Karlina García-Sosa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Karlina García-Sosa has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Luis Manuel Peña-Rodríguez
Centro de Investigación Científica de Yucatán, Chuburná de Hidalgo, Mérida, A.C., Yucatán, 97205, México
4 shared publications - Abraham Vidal-Limon
Red de Estudios Moleculares Avanzados, Clúster Científico y Tecnológico BioMimic®, Instituto de Ecología A.C. (INECOL), Xalapa 91073, Veracruz, Mexico
1 shared publication - Andrés Humberto Uc-Cachón
Unidad de Investigación Médica Yucatán, Instituto Mexicano del Seguro Social, Mérida 97150, Yucatán, Mexico
1 shared publication - Angel de Jesús Dzul-Beh
Unidad de Investigación Médica Yucatán, Instituto Mexicano del Seguro Social, Mérida 97150, Yucatán, Mexico
1 shared publication - Barry Hammel
Missouri Botanical Garden, St. Louis, USA
1 shared publication - Bartolomé Chi-Manzanero
Unidad de Biotecnología, Centro de Investigación Científica de Yucatán, A.C., Calle 43 No. 130 x 32 y 34, colonia Chuburná de Hidalgo, Mérida C.P. 97205, Yucatán, Mexico
1 shared publication
Latest Publications
- 19 March 2025
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 35 (2) , 373-381
A New Bioactive Cardenolide from Nerium oleander
- 19 March 2025
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 35 (2) , 373-381
A New Bioactive Cardenolide from Nerium oleander
- 26 May 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 42 (4) , 1692-1710
Bioassay-guided identification of antithrombotic compounds from Cnidoscolus aconitifolius (Mill.) I. M. Jhonst.: molecular docking, bioavailability, and toxicity prediction
Cardiovascular diseases (CVDs) are the leading cause of death worldwide. Conventional antithrombotic therapy has reported hemorrhagic accidents. Ethnobotanical and scientific reports point to Cnidoscolus aconitifolius as an antithrombotic adjuvant. Previously, C. aconitifolius leaves ethanolic extract displayed antiplatelet, anticoagulant, and fibrinolytic activities. This work aimed to identify compounds from C. aconitifolius with in vitro antithrombotic activity through a bioassay-guided study. Antiplatelet, anticoagulant, and fibrinolytic tests guided the fractionation. Ethanolic extract was subjected to a liquid-liquid partitioning, followed by vacuum liquid, and size exclusion chromatography to obtain the bioactive JP10B fraction. The compounds were identified through UHPLC-QTOF-MS, and their molecular docking, bioavailability, and toxicological parameters were determined computationally. Kaempferol-3-O-glucorhamnoside and 15(S)-HPETE were identified; both showed affinity for antithrombotic targets, low absorption, and safety for human consumption. Further in vitro and in vivo evaluations will better understand their antithrombotic mechanism. This bioassay-guided fractionation demonstrated that C. aconitifolius ethanolic extract has antithrombotic compounds.Communicated by Ramaswamy H. Sarma.
- 26 May 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 42 (4) , 1692-1710
Bioassay-guided identification of antithrombotic compounds from Cnidoscolus aconitifolius (Mill.) I. M. Jhonst.: molecular docking, bioavailability, and toxicity prediction
Cardiovascular diseases (CVDs) are the leading cause of death worldwide. Conventional antithrombotic therapy has reported hemorrhagic accidents. Ethnobotanical and scientific reports point to Cnidoscolus aconitifolius as an antithrombotic adjuvant. Previously, C. aconitifolius leaves ethanolic extract displayed antiplatelet, anticoagulant, and fibrinolytic activities. This work aimed to identify compounds from C. aconitifolius with in vitro antithrombotic activity through a bioassay-guided study. Antiplatelet, anticoagulant, and fibrinolytic tests guided the fractionation. Ethanolic extract was subjected to a liquid-liquid partitioning, followed by vacuum liquid, and size exclusion chromatography to obtain the bioactive JP10B fraction. The compounds were identified through UHPLC-QTOF-MS, and their molecular docking, bioavailability, and toxicological parameters were determined computationally. Kaempferol-3-O-glucorhamnoside and 15(S)-HPETE were identified; both showed affinity for antithrombotic targets, low absorption, and safety for human consumption. Further in vitro and in vivo evaluations will better understand their antithrombotic mechanism. This bioassay-guided fractionation demonstrated that C. aconitifolius ethanolic extract has antithrombotic compounds.Communicated by Ramaswamy H. Sarma.
Clusia suborbicularis is not a synonym of Clusia flava: Molecular and metabolomic evidence
The genus Clusia (Clusiaceae) is notorious for its difficult taxonomy; most species are dioecious, with distantly related species having similar morphology, and closely related species having cryptic morphological differences. Because of this, Clusia spp. are often misidentified or, as in the case of C. suborbicularis and C. flava, considered to be the same species. Chemometric analyses of the HPLC metabolic profiles from bark extracts of C. suborbicularis and C. flava, combined with molecular evidence from ITS molecular markers were used to establish the metabolomic similarities and phylogenetic relationship between C. suborbicularis and C. flava, previously identified on the basis of their morphological characteristics. The principal component analyses of the HPLC metabolic profiles of bark extracts from individuals of C. suborbicularis and C. flava showed significant differences, suggesting they should be recognized as distinct species. This assumption was confirmed by phylogenetic reconstructions based on the molecular marker ITS. Furthermore, a theoretical geographical distribution analysis suggests C. suborbicularis could be considered a native species to the Yucatán Peninsula. The results from this investigation support C. suborbicularis as a distinct species, and not a synonym of C. flava. The identification of these two species represents a relevant contribution for the cataloguing, conservation and bioprospecting of Clusia spp. occurring in the Yucatán Peninsula.
Clusia suborbicularis is not a synonym of Clusia flava: Molecular and metabolomic evidence
The genus Clusia (Clusiaceae) is notorious for its difficult taxonomy; most species are dioecious, with distantly related species having similar morphology, and closely related species having cryptic morphological differences. Because of this, Clusia spp. are often misidentified or, as in the case of C. suborbicularis and C. flava, considered to be the same species. Chemometric analyses of the HPLC metabolic profiles from bark extracts of C. suborbicularis and C. flava, combined with molecular evidence from ITS molecular markers were used to establish the metabolomic similarities and phylogenetic relationship between C. suborbicularis and C. flava, previously identified on the basis of their morphological characteristics. The principal component analyses of the HPLC metabolic profiles of bark extracts from individuals of C. suborbicularis and C. flava showed significant differences, suggesting they should be recognized as distinct species. This assumption was confirmed by phylogenetic reconstructions based on the molecular marker ITS. Furthermore, a theoretical geographical distribution analysis suggests C. suborbicularis could be considered a native species to the Yucatán Peninsula. The results from this investigation support C. suborbicularis as a distinct species, and not a synonym of C. flava. The identification of these two species represents a relevant contribution for the cataloguing, conservation and bioprospecting of Clusia spp. occurring in the Yucatán Peninsula.
- Open Access
- 1 November 2019
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 29 (6) , 798-800
In vitro growth inhibition and bactericidal activity of spathulenol against drug-resistant clinical isolates of Mycobacterium tuberculosis
- 1 November 2019
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 29 (6) , 798-800
Open AccessIn vitro growth inhibition and bactericidal activity of spathulenol against drug-resistant clinical isolates of Mycobacterium tuberculosis